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The  efﬁcacy  of a novel  topical  combination  of  ﬁpronil  8.3%  (w/v),  (S)-methoprene  10%  (w/v),
eprinomectin  0.4% (w/v),  and  praziquantel  8.3%  (w/v)  (BROADLINE®, Merial)  was  evaluated
against  adult  and  larval  Toxocara  cati  in  four  controlled  studies.  All studies  included  experi-
mentally infected,  purpose-bred,  short-haired  cats.  In two  studies,  22 or 20 cats  harbouring
patent  infections  as  conﬁrmed  by  pre-treatment  faecal  examination,  were  included.  Within
each study,  cats  were  allocated  to one  of  two  groups:  control  or  treated.  In a further  two
studies,  30  cats  were  included  in each;  cats  were  allocated  to one  of three  groups:  control,
treated  when  T.  cati  were  expected  to  be  either  migrating  third  and/or  fourth-stage  larvae,
or treated  when  T.  cati  were  expected  to be  fourth-stage  larvae.  Cats  allocated  to the treated
groups received  a single  topical  application  of  the combination  product  at 0.12  mL/kg  body-
weight  (10  mg  ﬁpronil  + 12 mg  (S)-methoprene  + 0.5  mg  eprinomectin  +  10 mg  praziquantel
per  kg).  For  parasite  recovery  and  count,  cats  were  euthanized  humanely  at different  inter-
vals  after  treatment.  In the  studies  targeting  adult  T. cati,  ascarids  were  recovered  from  all
controls  (range  1–150)  while  only  two  worms  were  isolated  from  one  treated  cat.  Thus, the
efﬁcacy  of  the  novel  combination  was  99.4%  and  100%  against  adult  T.  cati.  For  studies  tar-
geting larval  T. cati,  up to  21  worms  were  recovered  from  each  of  seven  or eight  of the  control
cats per study.  No  T.  cati  were  recovered  from  the treated  cats  in  two studies,  correspond-
ing to  100%  efﬁcacy  against  both,  migrating  third  and/or  fourth-stage  larvae  and  luminal
fourth-stage  larvae.  All  cats  accepted  the  treatment  well  and  no  adverse  experiences  or
other health  problems  were  observed  throughout  the studies.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
1. IntroductionThe ascarid Toxocara cati is a cosmopolitan parasite of
felids and represents the most common gastrointestinal
parasite of domestic cats worldwide (Bowman et al., 2002;
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Epe, 2009). Cats may  become infected with T. cati by three
different routes: by ingestion of larvated (infective) eggs,
by ingestion of paratenic hosts infected with somatic larval
T. cati, or by transmammary infection of suckling kittens.
It appears likely that the predominant route of infection
for the adult cat is the ingestion of paratenic hosts, such as
rodents and birds while kittens may  get infected soon after
birth when ingesting colostrum or milk from their infected
dam. The development of T. cati in the cat, as well as the
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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ole of paratenic hosts, has been studied by several authors
reviewed by Anderson, 2000; Bowman et al., 2002).
While there are some reports on clinical signs in cats
ssociated with ascarid infections like diarrhoea, potbelly,
oor coat and failure to thrive, it is well accepted that
he majority of cats do not show clinical signs (Aoki
t al., 1990; Bowman et al., 2002). However a recent
tudy demonstrated considerable pathology during pre-
atent development (Dillon et al., 2013). In paratenic
osts as well as in other accidental hosts (Azizi et al.,
007; Davidson et al., 2012), the development of T. cati is
imited basically to penetration and somatic migration of
hird-stage larvae and associated damage. Several reports
upport the hypothesis that along with other ascarids, T.
ati must be considered as a zoonotic agent that may  cause
uman toxocarosis exhibiting visceral larva migrans, ocu-
ar toxocarosis, neural larva migrans or covert toxocarosis
Fisher, 2003; Lee et al., 2010). In addition, epidemiolog-
cal studies suggest associations of human toxocarosis to
he development of allergic diseases, including asthma,
r epilepsy (Pinelli et al., 2006; Pinelli and Aranzamendi,
012; Quattrocchi et al., 2012). Infection risks for humans
re the result of direct contact with infected cats or through
he environment or food contaminated by the faeces of
nfected free-roaming cats (Overgaauw et al., 2009; Kłapec´
nd Borecka, 2012; Trejo et al., 2012). Periodic treatments
ith anthelmintics are considered an important measure
o reduce the frequency of patent ascarid infections in cats
nd the risk of transmission of infection to both other pets
nd humans (Deplazes et al., 2011; Overgauuw and van
napen, 2013).
The four studies reported here were conducted to
valuate the efﬁcacy of Broadline®,1 a novel topical com-
ination of ﬁpronil, (S)-methoprene, eprinomectin and
raziquantel, against adult and larval stages of T. cati in
ats.
. Materials and methods
The design of the studies was in accordance with the
nternational Cooperation on Harmonisation of Technical
equirements for Registration of Veterinary Medici-
al Products (VICH) – GL7, “Efﬁcacy of Anthelmintics:
eneral Requirements” (Vercruysse et al., 2001), VICH
L20 “Efﬁcacy of Anthelmintics: Speciﬁc Recommen-
ations for Felines” (Vercruysse et al., 2002), and the
World Association for the Advancement of Veterinary
arasitology (WAAVP) guidelines for evaluating the efﬁ-
acy of anthelmintics for dogs and cats” (Jacobs et al.,
994). All studies were conducted in compliance with
ICH GL9, entitled Good Clinical Practice and in com-
liance with local animal welfare legislation and were
pproved by an Independent Animal Care and Use
ommittee. All personnel involved in collecting efﬁcacy
ata were blinded to the treatment assignment of the
nimals.
1 Broadline® is a trademark of Merial; all other marks are the property
f  their respective owners.tology 202 (2014) 34–39 35
2.1. Experimental animals and inoculation
2.1.1. Efﬁcacy against adult T. cati
The studies against adult T. cati were conducted in
the USA (Study 1) and Germany (Study 2) with 22 or 20
purpose-bred short-haired cats, respectively. Cats weighed
between 1.23 and 2.91 kg prior to treatment and were
approximately 12–21 weeks old, respectively (Table 1).
The animals were either housed individually during the
entire study (Study 1) or in groups until seven days prior
to treatment and individually thereafter (Study 2). The
environmental conditions were identical for all animals
in a study. All cats were conﬁrmed negative for ascarid
eggs prior to inoculation by examination of faeces using
standard coproscopic techniques.
In both studies, each cat was inoculated orally on three
consecutive days (63, 62 and 61 days prior to treatment)
with approximately 100 infective (larvated) Toxocara eggs
per day. For inoculation, recent ﬁeld isolates (as deﬁned per
VICH GL 7, Vercruysse et al., 2001) originating from the USA
(Study 1) or Bulgaria (Study 2) were used (Table 1).
Faecal samples were collected either ﬁve or four days
prior to treatment and examined to conﬁrm the presence
of Toxocara eggs using quantitative ﬂotation techniques
(Study 1: modiﬁed Wisconsin technique; Study 2: modiﬁed
McMaster technique). All inoculated cats were shedding
Toxocara eggs prior to treatment (Study 1: 226–4902 eggs
per g of faeces [EPG]; Study 2: 1050–16,650 EPG) and were
included in the studies.
2.1.2. Efﬁcacy against larval T. cati
The studies against larval T. cati were conducted in
Germany (Studies 3 and 4) and included 30 purpose-bred,
short-haired cats each. Cats weighed between 1.0 kg and
2.5 kg prior to treatment and were approximately three to
four months old, respectively (Table 1).
Cats were housed individually (Study 4) or in groups
of six (Study 3) cats from study start until Day −8. From
Day −7 onwards, all animals were housed individually. Cats
were acclimated to the study facilities for seven days prior
to treatment. The environmental conditions were identical
for all animals in a study. All cats were conﬁrmed to be
negative for ascarid eggs by standard faecal examination
techniques prior to inoculation.
For each study, cats were inoculated orally once with
approximately 300 (Study 3), or 250 (Study 4) infective
(larvated) Toxocara eggs each. For inoculation, recent ﬁeld
isolates (as deﬁned per VICH GL 7, Vercruysse et al., 2001)
originating from Bulgaria (Study 3), and Germany (Study
4) were used (Table 1). In addition, cats in Study 3 were
inoculated with approximately 200 infective Ancylostoma
tubaeforme larvae, each (results not shown here but pre-
sented by Prullage et al., 2014).
2.2. Study design
The studies utilized a randomized block design based
on pre-treatment bodyweight. In the studies conducted to
evaluate the efﬁcacy against adult T. cati, cats were ranked
based on decreasing Day −3 bodyweight and placed in
replicates of two  cats, each. Within replicates, cats were
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Table 1
Characteristics of experimental animals and study design including day(s) of inoculation, number of Toxocara cati eggs provided, day of treatment and day of necropsy.
Inoculation of cats Treatment group Animal data Treatment Necropsy
Inoculation days Total number of
larvated T. cati eggs
inoculated
Age at treatment Sex Pre-treatment
bodyweight (kg)
Studies to evaluate the efﬁcacy against adult Toxocara cati
Study 1 Days −63, −62 and −61 ∼300b Untreated 12–14 weeks 10 Male, 1 female 1.89–2.81 – Day
7Treateda 9 male, 2 female 1.91–2.91 Day 0
Study  2 Days −63, −62 and −61 ∼300c Untreated 18–21 weeks 6 Male, 4 female 1.248–2.290 – Day 7
Treated 6 male, 4 female 1.229–2.214 Day 0
Studies  to evaluate the efﬁcacy against larval Toxocara cati
Study 3d Day −5 ∼300c
Untreated
13–14 weeks
5 Male, 5 female 1.035–1.538 –
Day 25Treated 5 male, 5 female 1.079–1.524 Day 0f
Treated 5 male, 5 female 1.015–1.904 Day 14g
Study 4 Day −5 ∼250e
Untreated
3–4 months
5 Male, 5 female 1.439–2.347 –
Day 24Treated 5 male, 5 female 1.290–2.080 Day 0f
Treated 5 male, 5 female 1.605–2.495 Day 14g
a Broadline® spot on for cats = ﬁpronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4%, w/v), and praziquantel (8.3%, w/v); at 0.12 mL/kg body weight.
b Origin of isolate: naturally infected cat from Tennessee, USA; isolated eggs were incubated and directly used within two  months from isolation.
c Origin of isolate: naturally infected cat from Bulgaria; isolate maintained for three years in laboratory through passages in cats.
d Cats additionally inoculated with ∼200 A. tubaeforme larvae on Day −7; data shown in Prullage et al. (2014).
e Origin of isolate: naturally infected cat from Germany; isolated eggs were incubated and directly used within six months from inoculation.
f T. cati expected to be migrating third and/or fourth-stage larvae.
g T. cati expected to be fourth-stage larvae.
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llocated randomly to one of two groups: one to the
ntreated control group and one to the group treated with
he novel topical formulation. In the studies conducted to
valuate the efﬁcacy against larval T. cati, cats were ranked
ased on decreasing Day −3 or −1 bodyweight and placed
n replicates of three cats, each. Within replicates, cats
ere allocated randomly to one of three treatment groups:
ntreated (control) group, a group treated when T. cati were
xpected to be migrating third and/or fourth-stage larvae
ﬁve days post inoculation), or a group treated when T. cati
ere expected to be luminal fourth-stage larvae (19 days
ost inoculation) (Vercruysse et al., 2002).
The treatment, ﬁpronil 8.3% (w/v), (S)-methoprene 10%
w/v), eprinomectin 0.4% (w/v), praziquantel 8.3% (w/v),
Broadline®, Merial), was administered once topically at
he minimum therapeutic dose of 0.12 mL/kg bodyweight
irectly on the skin in the midline of the neck between
he base of the skull and the shoulder blades in a single
pot. All cats were observed hourly for 4 h post-treatment
nd thereafter once daily until end of the study for health
roblems or adverse events.
.3. Parasite recovery and count
For parasite recovery and count, cats were euthanized
umanely at different intervals after treatment (Table 1).
he content of the whole gastrointestinal tract (includ-
ng stomach, small and large intestine) was collected. To
acilitate the isolation and counting of ascarids, organ
ontents were washed through appropriate sized sieves to
emove debris. Counts were made on total gastrointesti-
al contents. Parasites were identiﬁed to species and stage
ased on morphological characteristics.
.4. Data analysis
For all studies, parasite counts (adult T. cati, Studies
 and 2; total T. cati, Studies 3 and 4) were transformed
o the natural logarithm of (count +1) for calculation of
eometric means for each treatment group. Efﬁcacies for
he treated groups were determined by calculating the
ercent efﬁcacy as 100[(C − T)/C], where C was the geomet-
ic mean of the parasite count for the untreated (control)
able 2
arasite counts and therapeutic efﬁcacy of Broadline® spot-on for cats against dif
Target parasite stage Study Untreated (c
NI/NGd
Adult T. cati 1 11/11 
2  10/10 
Luminal fourth-stage T.
cati larvae
3 7/10 
4  9/10 
Migrating third and/or fourth-stage T. cati larvae 3 7/10 
4  9/10 
a Topical ﬁpronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4%, w
b Efﬁcacy = 100 [(geometric mean untreated (control) group − geometric mean
c Two-sided p-value comparing the worm burden of the topical FMEP group w
d NI/NG: Number of cats infected/number of cats in group.
e GM:  geometric mean count (based on transformation to ln [count + 1]).
f Studies 1 and 2: adult T. cati; Studies 3 and 4: total T. cati.tology 202 (2014) 34–39 37
animals and T was  the geometric mean of the parasite count
of the treated group. The log-counts of each treated group
were compared to the log-counts of the untreated (con-
trol) group using a F-test adjusted for the allocation blocks
used to randomize the animals to the treatment groups.
The Mixed procedure in SAS® was  used for the analysis
with the treatment groups deﬁned as a ﬁxed effect and the
allocation blocks deﬁned as a random effect. All testing was
two-sided at the  ˛ = 0.05 signiﬁcance level.
3. Results
No adverse experiences or other health problems
were observed after treatment application or through-
out the studies, indicating that the treatment was well
accepted.
The results of the studies are summarized in Table 2.
Between 1 and 150 adult T. cati were recovered from the
untreated cats in studies 1 and 2, while only 2 T. cati were
recovered from one of the cats treated with the novel com-
bination in Study 1. The therapeutic efﬁcacy of the novel
topical combination product against adult T. cati was  thus
99.4% in study 1 and 100% in study 2 (P < 0.001). In addition
to adult worms, small numbers of immature T. cati were
recovered from some cats in both studies (1–14 larvae per
cat in 9 of 11 untreated animals vs. 1 larva in 1 of 11 treated
animals in Study 1; 1–7 larvae each in 8 of 10 untreated
animals vs. 3 larvae in 1 of 10 treated animals in Study 2).
The mean establishment rate (percentage ratio of number
of total nematodes in controls found at necropsy vs. num-
ber of eggs inoculated) was 13.2% and 27.6% in Studies 1
and 2, respectively, with 89.7% and 97.2% of the total T. cati
burden consisting of adult parasites.
In Studies 3 and 4, seven and nine cats out of ten con-
trols, respectively, harboured between 1 and 21 T. cati
(fourth-stage larval and/or pre-adult stages), correspond-
ing to establishment rates of 2.6% and 1.8%, respectively.
Zero T. cati were recovered from the treated cats in Stud-
ies 3 and 4, corresponding to 100% efﬁcacy (P < 0.001)
against both migrating third and/or fourth-stage and lumi-
nal fourth-stage larvae.
All studies were considered valid as they met the recom-
mendations as to adequacy-of-infection per VICH GL7 and
ferent developmental stages of experimentally induced Toxocara cati.
ontrol) Topical FMEPa Efﬁcacy (%)b P-valuec
GMe (range)f NI/NG GM (range)f
17.43 (1–131) 1/11 0.11 (0–2) 99.4 <0.001
70.9 (37–150) 0/10 0 100 <0.001
5.14 (0–21) 0/10 0 100 <0.001
3.3 (0–10) 0/10 0 100 <0.001
5.14 (0–21) 0/10 0 100 <0.001
3.3 (0–10) 0/10 0 100 <0.001
/v), and praziquantel (8.3%, w/v); at 0.12 mL/kg body weight.
 topical FMEP group)/geometric mean untreated (control) group].
ith the control.
y Parasi38 M. Knaus et al. / Veterinar
VICH GL20 with at least six control animals harbouring at
least ﬁve T. cati each.
4. Discussion
These studies conﬁrmed the high therapeutic efﬁcacy of
topical ﬁpronil, (S)-methoprene, eprinomectin and praz-
iquantel against adult and larval T. cati infections. The
results of these studies demonstrated that the combination
product is efﬁcacious against T. cati during the immature
stages while the parasite is developing within the cat host.
This feature is important as this effect contributes to a more
sustainable prevention of ascarid infections in cats and thus
reduces the risk of transmission of infection.
The high level of efﬁcacy against both larval stages and
adults T. cati in experimentally infected cats is supported by
the results of other controlled studies using the novel top-
ical combination formulation in naturally infected animals
(Knaus et al., 2014) and under ﬁeld conditions involving
cats from seven countries in Europe (Rehbein et al., 2014).
Geometric mean total adult T. cati counts of the con-
trol animals in the four studies ranged from 3.3 to 70.9.
These numbers are consistent with observations in other
studies utilizing similar doses of 200–400 infective eggs for
inoculation of cats (e.g., Reinemeyer et al., 2005; Schenker
et al., 2007; Wolken et al., 2012). As indicated by the
rates of establishment (including ratios of number of cats
infected/number of cats in group) inoculation of higher
doses of infective eggs as a single bolus (Studies 3 and 4)
resulted in lower worm counts and a higher number of
uninfected cats compared to the inoculation of lower doses
of infective eggs over three consecutive days (Studies 1 and
2). It has been known for quite some time that immuno-
logical reactions play a signiﬁcant role in the host–parasite
interaction during the initial phase of infection of cats with
T. cati (Sarles and Stoll, 1935). Therefore, the ﬁndings from
our studies suggest that single exposure to higher doses of
infective T. cati eggs stimulates host reactions to a greater
extent than does multiple exposures to smaller number
of infective eggs that result in lower numbers of parasites
undergoing development.
Macrocyclic lactones have been used as anthelmintics
in cats for several years and provide excellent efﬁcacy
against infections with various nematode parasites of pets
(reviewed by Guerrero et al., 2002; Nolan and Lok, 2012).
The results suggest that the novel topical combination
product containing eprinomectin will provide an efﬁca-
cious, safe and convenient solution for the treatment of
adult and larval stages of T. cati in cats.
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